Could an old HIV drug help eliminate stubborn Low-Level virus?

NCT ID NCT06823596

First seen Jan 09, 2026 · Last updated May 16, 2026 · Updated 23 times

Summary

This study tests whether adding the HIV drug efavirenz to a person's regular antiretroviral therapy (ART) can kill cells that still harbor HIV, even when the virus is well-controlled. About 26 adults with HIV who have very low but detectable virus levels despite good medication adherence will take efavirenz for 8 weeks. The goal is to see if this approach can reduce or eliminate that remaining virus, which may help improve long-term health and bring us closer to an HIV cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Maple Leaf Medical Clinic

    RECRUITING

    Toronto, Ontario, M5G 1K2, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Unity Health Toronto -St. Michael's Hospital

    RECRUITING

    Toronto, Ontario, M5B 1W8, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.